SCHEMBL1769351

SCHEMBL1769351

N#CC1(c2ccccc2F)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 2/20 0.41
ALDH1A1 P00352 2/20 0.40
NPC1 O15118 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BDKRB1 P46663 1/20 0.37
OPRM1 P35372 2/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
OPRL1 P41146 1/20 0.37
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30929543 1.00 HDAC4 (0.41) HDAC4ALDH1A1NPC1LMNATP53
SCHEMBL1020368 0.92 NPC1 (0.48) HDAC4ALDH1A1NPC1LMNATP53
SCHEMBL625354 0.92 NPC1 (0.44) HDAC4ALDH1A1NPC1LMNATP53
SCHEMBL1018309 0.90 NPC1 (0.47) HDAC4ALDH1A1NPC1LMNATP53
SCHEMBL615034 0.87 OPRM1 (0.37) HDAC4ALDH1A1NPC1LMNATP53
SCHEMBL30338086 0.87 OPRM1 (0.37) HDAC4ALDH1A1NPC1LMNATP53
SCHEMBL4006359 0.87 ALDH1A1 (0.37) HDAC4ALDH1A1NPC1LMNATP53
SCHEMBL14341357 0.86 ALDH1A1 (0.34) HDAC4ALDH1A1NPC1LMNATP53
SCHEMBL10526403 0.86 OPRM1 (0.39) ALDH1A1NPC1RAB9ASMN1; SMN2OPRM1
SCHEMBL16113514 0.86 HDAC4 (0.45) HDAC4ALDH1A1NPC1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024118810-A1 CYCLIC PYRAZOLE DIAMIDE IRE1/XBP1S ACTIVATORS PROTEGO BIOPHARMA, INC. (US) 2024-06-06 WO disclosed
CN-113861072-A Preparation method of aryl cyclopropane compound 上海麦克林生化科技有限公司 2021-12-31 CN disclosed
WO-2011061760-A1 NOVEL ANTITHROMBOTIC AGENTS CADILA HEALTHCARE LIMITED (IN) 2011-05-26 WO disclosed
US-20090312558-A1 PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPOANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM RELIANCE LIFE SCIENCES PVT. LTD. (IN) 2009-12-17 US disclosed
WO-2009150660-A1 A PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM RELIANCE LIFE SCIENCES PVT. LTD. (IN) 2009-12-17 WO disclosed
US-4859232-A Substituted-aryl cyclopropanecarbonitriles and derivatives thereof as herbicide antidotes MONSANTO COMPANY (US) 1989-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312558-A1 PROCESS FOR THE PREPARATION OF ARYLCYCLOPROPOANE CARBOXYLIC CARBONITRILES, AND COMPOUNDS DERIVED THEREFROM NOTUM, SULT2A1, SULT1A1 HDAC4 4498/4885ALDH1A1 204/4885NPC1 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.